CRISPR editing isn’t the bottleneck anymore. Scaling it is.

Scaling isn’t just about producing more. The challenge is making CRISPR workflows reliable, reproducible, and scalable, while balancing speed, flexibility, and rigor across development. In this webinar, you’ll get a technical look at how Synthego approaches these challenges, and what that means for your CRISPR program as you progress toward clinical applications.

In this session, you’ll learn about:

  • The key challenges of scaling CRISPR-based therapies, and what it takes to maintain consistency and quality as you move your programs toward clinical stages
  • The importance of analytical qualification and validation strategies to assess quality, purity, and clinical readiness
  • Considerations for integrating gRNA and nuclease manufacturing with quality systems and regulatory requirements across IND-enabling and GMP stages

tyler winick

Tyler Winick is Director of Chemistry Development at Synthego, where he has spent the past 7 years advancing scalable CRISPR manufacturing technologies for research and clinical applications. He leads teams focused on gRNA chemistry, process development, analytical qualification, and manufacturing strategies that support progression from early-stage development through GMP production.

cirm logo

In collaboration with the California Institute for Regenerative Medicine (CIRM).